Enhancement of bone regeneration by gene delivery of BMP2/Runx2 bicistronic vector into adipose-derived stromal cells.
Lee SJ., Kang SW., Do HJ., Han I., Shin DA., Kim JH.
Animal Study, published in Biomaterials (2010) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Biomaterials (2010)
- Country
- Netherlands
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 20413153
- DOI
- 10.1016/j.biomaterials.2010.03.019
- Citations
- 80
Abstract (original English)
Adipose tissue contains multipotent mesenchymal stem cells (MSCs) that are able to differentiate into various tissues. Bone morphogenetic protein 2 (BMP2) is known as one of the key osteogenesis induction factors in MSCs. Recently, several new transcription factors that contribute to osteogenic differentiation have been reported, among them Runx2, Osterix, and Dlx5. We hypothesized that adipose-derived stromal cells (ASCs) could be induced to efficiently differentiate into osteocytes by the co-expression of the BMP2 and Runx2 genes. To prove this hypothesis, we constructed a bicistronic vector encoding the BMP2 and Runx2 genes linked to the 'self-cleaving' 2A peptide sequence. BMP2/Runx2-ASCs showed a gradual increase in alkaline phosphatase activity for two weeks. RT-PCR analysis and alizarin red staining revealed a high expression of osteogenesis-related markers (osteopontin, osteocalcin and collagen type I) and increased mineralization in BMP2/Runx2-ASCs compared to BMP2-ASCs. Six weeks after in vivo transplantation, BMP2/Runx2-ASCs also showed a significant increase in bone formation compared to ASCs and BMP2-ASCs. These findings demonstrate that the co-transfection of two osteogenic lineage-determining genes can enhance osteogenic differentiation of ASCs.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.